Citing people familiar with the situation, the newspaper said Bausch & Lomb -- based in Rochester, N.Y., and owned by private-equity firm Warburg Pincus LLC -- could reach a deal with generic drug maker Valeant by next week.
One source cautioned the deal hasn't been finalized and could still collapse.
If the sale falls through, Warburg and Bausch & Lomb could go ahead with a planned initial public offering of stock in the eye-care company, the Journal said.
Video of Victoria’s Secret models trying to 'twerk' hits Instagram
Wisconsin business offering 'therapeutic cuddling' forced to close